RxCell develops cellular therapeutics using induced pluripotent stem cell (iPSC)-derived retinal photoreceptors (RPCs) and combinations of RPC and RPE to restore vision in patients with advanced photoreceptor loss. The company aims to demonstrate the value of its RPC product in an upcoming Phase I/IIA clinical trial targeting retinitis pigmentosa (RP) patients. RxCell is preparing an IND application and plans IND testing supported by a planned capital raise. The firm announced a $4.6M investment commitment and is planning a further $15M raise in Q4 2023 to advance IND-stage activities. RxCell cites collaborations with NUS, A*STAR’s IMCB, and SERI as part of its R&D ecosystem. The company framed its work within the broader AMD market, noted as having been valued at $7.47 billion in 2021 and projected to grow at a 7.9% CAGR through 2030.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2023